Select your country or region to view content specific to your country.
Jan 17, 2022
- Seegene
to export COVID-19 test that detects COVID-19 and Omicron along with its Master
Assay that distinguishes between COVID-19 and other respiratory viruses
Seegene Inc. (KQ 096530), South Korea's
leading molecular diagnostics company, announced today that it has delivered over five million COVID-19 tests to Israel to help detect and mitigate
the spread of the Omicron variant. The company sent 1.7 million diagnostic
tests and associated consumables in December 2021, while additional 3.4 million
tests are scheduled to be delivered in January.
Like much of the world, Israel started to experience
a shortage of COVID-19 tests as Omicron was driving an unprecedented surge in
cases. More seriously, the number of flu or ‘flurona’ patients who may be co-infected with flu and COVID-19 seems
to increase this winter. Seegene’s prompt delivery of COVID-19 tests is
expected to cover approximately 57% of Israel’s total 9 million population and
play a crucial role in controlling the potential ‘twindemic’ season.
“We will continue to support countries in need
of COVID-19 tests to improve global health,” said Dr. Jong-Yoon Chun, Seegene
Founder, and CEO. “It is apparent that Seegene’s accurate COVID-19 tests screening
all COVID 19 variants and syndromic tests with the respiratory essential panel
are going to be a key to the global effort of returning to normal. Both tests
will also help to manage lives with COVID-19 and other respiratory infections.”
Seegene will send various products to Israel, including its Allplex™ SARS-CoV-2 Master Assay and Allplex™ SARS CoV-2 FluA/FluB/RSV Assay.
- Seegene's Allplex™ SARS-CoV-2 Master Assay can quickly determine the spread of the new Omicron variant in real-time with multiplex PCR technology, rapidly identifying positive cases and those variants in a single reaction.
- Allplex™ SARS CoV-2 FluA/FluB/RSV Assay can determine the exact cause of respiratory symptoms. A single test can distinguish between Influenza A and B, RSV, and COVID-19.